Sorry, this is only available to registered users
BVMT provides data to our registered users only, so to get it you'll need to sign up for a TradingView account.
0.20 TND
5.55 M TND
136.00 M TND
5.68 M
About UNITÉ DE FABRICATION DE MÉDICAMENTS
Sector
CEO
Ridha Charfeddine
Headquarters
Sousse
Website
Founded
1989
ISIN
TN0007720014
FIGI
BBG00CTZNHT0
Unité de Fabrication de Médicaments is a holding company, which engages in the manufacture of pharmaceutical products. It offer generic drugs such as furoxem, bupicaine, mydricol, rachianestehesie,doperan, furoxem, levoject, ketomed, amoxil, ampicil, cefaxone, oflocol, and cefazol. The company was founded by Ridha Charfeddine in 1989 and is headquartered in Sousse, Tunisia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BVMT exchange UNITÉ DE FABRICATION DE MÉDICAMENTS stocks are traded under the ticker UMED.
Today UNITÉ DE FABRICATION DE MÉDICAMENTS has the market capitalization of 227.20 M, it has decreased by −1.39% over the last week.
Yes, you can track UNITÉ DE FABRICATION DE MÉDICAMENTS financials in yearly and quarterly reports right on TradingView.
UMED net income for the last half-year is 7.56 M TND, while the previous report showed −1.13 M TND of net income which accounts for 769.37% change. Track more UNITÉ DE FABRICATION DE MÉDICAMENTS financial stats to get the full picture.
Yes, UMED dividends are paid annually. The last dividend per share was 0.47 TND. As of today, Dividend Yield (TTM)% is 6.61%. Tracking UNITÉ DE FABRICATION DE MÉDICAMENTS dividends might help you take more informed decisions.
UNITÉ DE FABRICATION DE MÉDICAMENTS dividend yield was 0.00% in 2023, and payout ratio reached 0.00%. The year before the numbers were 6.59% and 191.66% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UNITÉ DE FABRICATION DE MÉDICAMENTS EBITDA is 43.37 M TND, and current EBITDA margin is 30.27%. See more stats in UNITÉ DE FABRICATION DE MÉDICAMENTS financial statements.
Like other stocks, UMED shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UNITÉ DE FABRICATION DE MÉDICAMENTS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So UNITÉ DE FABRICATION DE MÉDICAMENTS technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating UNITÉ DE FABRICATION DE MÉDICAMENTS stock shows the sell signal. See more of UNITÉ DE FABRICATION DE MÉDICAMENTS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.